ZyVersa Therapeutics
ZyVersa Therapeutics is a biopharmaceutical company developing novel therapies for inflammatory and kidney diseases, including the monoclonal antibody IC 100 and the cholesterol efflux mediator VAR 200, targeting a combined market opportunity of over $75 billion.
Company Overview
ZyVersa Therapeutics focuses on developing first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. The company develops innovative therapeutic solutions aimed at significant medical conditions, leveraging their unique approach to address specific disease mechanisms in these critical areas.
IC 100 Monoclonal Antibody
ZyVersa Therapeutics is developing IC 100, a novel monoclonal antibody targeting the ASC component of the inflammasome. This innovative approach aims to inhibit multiple types of inflammasomes, which are involved in the initiation and continuation of inflammatory cascades. By targeting ASC, IC 100 has the potential to treat central nervous system (CNS) and other inflammatory diseases.
VAR 200 Cholesterol Efflux Mediator
ZyVersa Therapeutics is advancing VAR 200, a cholesterol efflux mediator designed to remove excess cholesterol from the kidney’s filtration system. The active ingredient in VAR 200 is 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), which has demonstrated efficacy in preclinical studies to facilitate cholesterol removal from podocytes. VAR 200 is prepared for a Phase 2a trial targeting focal segmental glomerulosclerosis (FSGS) with potential applications in Alport syndrome and diabetic kidney disease.
Target Markets
ZyVersa Therapeutics addresses markets exceeding $75 billion with their innovative drug candidates. Focused on inflammatory and kidney diseases, the company positions itself in niches like inflammasome inhibition and cholesterol efflux mediation, addressing diseases like CNS inflammatory disorders and focal segmental glomerulosclerosis (FSGS).
Focus on Unmet Medical Needs
ZyVersa Therapeutics targets diseases with high unmet medical needs, particularly in the realm of inflammatory and kidney diseases. Their commitment to first-in-class drugs places them at the forefront of new therapeutic developments, addressing critical gaps in medical treatment options for conditions that significantly impact patient health and quality of life.
